Plain-English translation of NCT06785636 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new drug called to see if it can help people with advanced prostate cancer that has stopped responding to standard treatments. The study will test the medication both on its own and combined with another prostate cancer drug called darolutamide. Researchers want to find the right dose and understand how well this treatment works and what side effects it may cause.
Prostate cancer that no longer responds to standard hormone therapies is very difficult to treat, and patients need new options. This medication is being studied because early research suggests it may help slow or stop cancer growth in patients who have already tried other treatments.
You likely qualify if…
You likely don't qualify if…
You will take the study medication by mouth, either as a single agent or combined with another prostate cancer drug, depending on which study arm you join. The trial has two phases: in Phase 1b, researchers will test different doses to find the safest and most effective level; in Phase 2a, a larger group will receive the recommended dose to learn more about how well it works. Throughout the study, you'll have regular clinic visits for blood tests, imaging scans, and checkups to monitor your cancer and watch for side effects.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States